Skip to content

Inhibrx Biosciences

US · INBX #3022 by market cap Listed 2024
68.97 -5.36 -7.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Earnings Flash (INBX) Inhibrx Biosciences, Inc. Reports Q3 Revenue $2.0M
    MT Newswires · 2026/11/14
  • Rating change
    Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $300
    Market Newswire · 2026/4/22
  • Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL)
    TipRanks · 2026/9/9
  • Rating change
    LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230
    Market Newswire · 2026/9/8
  • Rating change
    Stifel Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $150
    Market Newswire · 2026/4/17
  • Rating change
    JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
    Market Newswire · 2025/3/19
  • H.C. Wainwright Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $245
    Market Newswire · 2026/9/9
  • Rating change
    LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230
    Market Newswire · 2026/5/11
  • Rating change
    LifeSci Capital Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $200
    Market Newswire · 2026/4/24
  • Company notice
    Inhibrx: Inhibrx, Inc. - Distribution Option Symbol: INBX New Symbol: INBX1
    OCC · 2024/5/30
  • Rating change
    LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200
    Market Newswire · 2026/4/26
  • Rating change
    Citizens JMP Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
    Market Newswire · 2025/5/16
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)
    TipRanks · 2026/5/11
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Inhibrx (INBX)
    TipRanks · 2023/11/20
  • Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325
    Market Newswire · 2026/10/29
  • H.C. Wainwright Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $245
    Market Newswire · 2026/8/25
  • Rating change
    Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325
    Market Newswire · 2026/5/15
  • Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325
    Market Newswire · 2026/8/21

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Inhibrx Biosciences discussion 0 comments

Add a comment